A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Trial Profile

A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Exenatide (Primary) ; Empagliflozin; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms FREEDOM-4-OAD
  • Sponsors Intarcia Therapeutics
  • Most Recent Events

    • 27 Jan 2018 Status changed from active, no longer recruiting to discontinued as per sponsors decision.
    • 08 Nov 2017 This trial has beeen completed in Netherlands.
    • 19 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top